

FAX TRANSMITTAL SHEET  
KLAUBER & JACKSON  
ATTORNEYS AT LAW  
CONTINENTAL PLAZA  
411 HACKENSACK AVENUE  
HACKENSACK, NJ 07601

PHONE (201) 487-5800

RECEIVED

26 JUL 2006

Legal Staff  
International Division

FAX (201) 343-1684 OR  
(201) 343-7544

TO : USPTO - PCT Legal Administrator  
FROM : David A. Jackson, Esq.  
RE : Serial No.: 10/524,910 - Attorney Docket No. 2543-1-040PCT/US  
3<sup>RD</sup> REQUEST FOR CORRECTED FILING RECEIPT - TITLE  
DATE : July 26, 2006  
FAX NO. : (571) 273-0459

TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 13

MESSAGE:

Attached herewith is a COPY of our Request for a Corrected Filing Receipt (correction to the Title of the application), originally filed on March 22, 2006, with a 2<sup>nd</sup> Request filed on April 28, 2006.

Please issue a Corrected Filing Receipt reflecting the Title *PTK7 Protein Involvement in Carcinoma*.

Thank you.

NOTE: The information contained in this facsimile message is attorney-client privileged and contains confidential information intended only for the use of the individual named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (201-487-5800) and return the original transmission to us by mail without making a copy.

FAX TRANSMITTAL SHEET  
KLAUBER & JACKSON  
ATTORNEYS AT LAW  
CONTINENTAL PLAZA  
411 HACKENSACK AVENUE  
HACKENSACK, NJ 07601

PHONE (201) 487-5800

2ND REQUEST  
4/28/06

FAX (201) 343-1684 OR  
(201) 343-7544

TO : USPTO - PCT Legal Administrator  
FROM : David A. Jackson, Esq.  
RE : Serial No.: 10/524,910 - Attorney Docket No. 2543-1-040PCT/US  
REQUEST FOR CORRECTED FILING RECEIPT - TITLE  
DATE : March 22, 2006  
FAX NO. : (571) 273-0459

TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET):

12

MESSAGE:

Attached herewith is a Request for Corrected Filing Receipt (correction to the Title of the application). Since this is a National Phase Filing, we have been advised that such requests should be directed to the PCT Legal Administrator.

Kindly process the correction to the Title to read: *PTK7 Protein Involvement in Carcinoma* and issue a Corrected Filing Receipt.

Thank you.

NOTE: The information contained in this facsimile message is attorney-client privileged and contains confidential information intended only for the use of the individual named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (201-487-5800) and return the original transmission to us by mail without making a copy.

PATENT  
2543-1-040PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) : Jonathan Alexander Terrett  
SERIAL NO. : 10/524,910  
FILED : January 12, 2006  
FOR : PTK7 PROTEIN INVOLVEMENT IN CARCINOMA

CERTIFICATE OF FACSIMILE UNDER 37 CFR 1.8

I hereby certify that this correspondence is being transmitted via facsimile to  
addressed to PCT Legal Administrator, Commissioner For Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450 on MARCH 22, 2006.

Karen Garipoli  
(Name of Transmitter)

Karen Garipoli 3/22/06  
(Signature and Date)

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Attn: PCT Legal Administrator

Dear Sir:

Applicants hereby request that a corrected Formal Filing Receipt (PTO-103X) be issued to  
correct the title in the above-identified Application.

Please correct the title from "Protein Involved in Carcinoma" to

~~XXXXXX~~

--PTK7 PROTEIN INVOLVEMENT IN CARCINOMA--

~~XXXXXX~~

as it appears on the first page of the Application as filed on February 17, 2005, as well as on the  
executed Declaration filed with the Response to the Notification of Missing Requirements on  
January 12, 2006. Copies of the first page of the application and the executed Declaration are


attached herewith

PATENT  
2543-1-040PCT/US

A copy of the filing receipt with the requested correction marked in red is also enclosed.

Applicants accordingly request that the records of the U.S. Patent and Trademark Office  
be corrected to reflect the correct title.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "David A. Jackson", is written over a horizontal line.

David A. Jackson  
Attorney for Applicant  
Registration No. 26,742

KLAUBER & JACKSON LLC  
411 Hackensack Avenue, 4<sup>th</sup> Floor  
Hackensack, NJ 07601  
(201) 487-5800

Enclosures



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/524,910	01/12/2006	1615	1980	2543-1-040PCT/US	10	31	5

CONFIRMATION NO. 1458

23565

KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NJ 07601

RECEIVED

FILING RECEIPT

100000000018267677

MAR 20 2006

KLAUBER &amp; JACKSON

Date Mailed: 03/15/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Jonathan Alexander Terrett, Berkshire, GBN, UNITED KINGDOM;

Power of Attorney: The patent practitioners associated with Customer Number 23565.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB03/03421 08/06/2003

## Foreign Applications

UNITED KINGDOM 0219776.2 08/24/2002

Projected Publication Date: 06/22/2006

Non-Publication Request: No

Early Publication Request: No

Title:

PTK7 Protein Involvement  
in carcinoma

Preliminary Class

Correct title to read:

PTK7 Protein Involvement  
IN CARCINOMA

3/22/06

424

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An International (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

### LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the

national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau.



**(43) International Publication Date**  
**4 March 2004 (04.03.2004)**

**PCT**

**(10) International Publication Number**  
**WO 2004/017992 A3**

(51) International Patent Classification: A61K 39/395,  
38/17, A61P 35/00

(74) Agent: **BLAKEY, Alison, Jane**; Oxford GlycoSciences (UK) Ltd, The Forum, 86 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

**(21) International Application Number:**  
**PCT/GB2003/003421**

(22) International Filing Date: 6 August 2003 (06.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0219776.2

(71) Applicant (for all designated States except US): OXFORD GLYCOSCIENCES (UK) LTD (GB/GB); Attn: Mary Gadsden, The Forum, 86 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): TERRETT, Jonathan, Alexander [GB/GB]; The Forum, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KB, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report

*[Continued on next page]*

(54) Title: PTK7 PROTEIN INVOLVEMENT IN CARCINOMA



(57) Abstract: The present invention provides a polypeptide, PTK7, of use in the treatment and/or prophylaxis of carcinoma. Also provided are agents which interact with or modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of PTK7 in the diagnosis of carcinoma.

**WO 2004/017992 A3**



Under the Paperwork Reduction

of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
or use through 3/31/2007, OMB 0851-0021**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**ATTORNEY'S DOCKET NUMBER  
2543-1-040PCT/US

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.  
PCT/OB2003/003421INTERNATIONAL FILING DATE  
August 6, 2003PRIORITY DATE CLAIMED  
August 24, 2002

## TITLE OF INVENTION

PTK7 PROTEIN INVOLVEMENT IN CARCINOMA

APPLICANT(S) FOR DO/EO/US

JONATHAN ALEXANDER TERRETT

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a submission under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a submission under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). **UNEXECUTED**
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 35 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A preliminary amendment.
14. ☐ An Application Data Sheet under 37 CFR 1.76.
15. ☐ A substitute specification.
16. ☐ A power of attorney and/or change of address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.
18. ☐ A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: **DRAWINGS-10 SHEETS-FIG.1-9; COPY ISR; COPY IPER; SEQ LIST-PAPER; SEQ. STATEMENT; COPY PCT REQ; COPY NOTICE CONCERN TRANSMIT PRIORITY; COPY DEMAND**

This collection of information is required by 37 CFR 1.414 and 1.481-1.482. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

EXPRESS MAIL NO.: EV 247182598 US

DATE OF DEPOSIT: FEBRUARY 17, 2005

Attorney Docket No.:2543-1-040PCT/US

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**PTK7 PROTEIN INVOLVEMENT IN CARCINOMA**

the Specification of which

☒ is attached hereto

☒ was filed on August 6, 2003

as International Application No. PCT/GB2003/003421

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

<u>APPLICATION</u> <u>NUMBER</u>	<u>PRIOR FOREIGN FILED APPLICATION(S)</u> <u>COUNTRY</u> ( <u>MONTH/DAY/YYYY</u> )	<u>PRIORITY</u> <u>CLAIMED</u>
0219776.2	Great Britain August 24, 2002	YES

Attorney Docket No.:2543-1-040PCT/US

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER(S)FILING DATE (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent  
Application No.

PCT Parent  
Number

Parent Filing  
(MM/DD/YYYY)

Parent Patent  
Number (if applicable)

I hereby appoint as my attorneys or agents the registered persons identified under

**Customer No. 23565**

for the law firm of Klauber & Jackson, said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to **Customer No. 23565**.

DAVID A. JACKSON, ESQ.  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

Attorney Docket No.:2543-1-040PCT/US

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST OR SOLE INVENTOR: Jonathan Alexander TERRETT

COUNTRY OF CITIZENSHIP: Great Britain

FULL RESIDENCE ADDRESS: 208 Bath Road  
Slough, Berkshire  
SL1, 3WE  
Great Britain

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR 

DATE

Feb 17<sup>th</sup> 2005

\*\*\* TX REPORT \*\*\*  
\*\*\*\*\*

TRANSMISSION OK

TX/RX NO 3105  
DESTINATION TEL # 15712730459  
DESTINATION ID  
ST. TIME 04/28 14:52  
TIME USE 01'31  
PAGES SENT 12  
RESULT OK

**FAX TRANSMITTAL SHEET**  
**KLAUBER & JACKSON**  
**ATTORNEYS AT LAW**  
**CONTINENTAL PLAZA**  
**411 HACKENSACK AVENUE**  
**HACKENSACK, NJ 07601**  
  
**PHONE (201) 487-5800**

*2ND REQUEST*  
*4/28/06*

**FAX (201) 343-1684 OR**  
**(201) 343-7544**

**TO : USPTO - PCT Legal Administrator**  
**FROM : David A. Jackson, Esq.**  
**RE : Serial No.: 10/524,910 - Attorney Docket No. 2543-1-040PCT/US**  
**REQUEST FOR CORRECTED FILING RECEIPT - TITLE**  
**DATE : March 22, 2006**  
**FAX NO. : (571) 273-0459**

**TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET):**

**12**

**MESSAGE:**

Attached herewith is a Request for Corrected Filing Receipt (correction to the Title of the application). Since this is a National Phase Filing, we have been advised that such requests should be directed to the PCT Legal Administrator.

Kindly process the correction to the Title to read: *PTK7 Protein Involvement in Carcinoma* and issue a Corrected Filing Receipt.

**Thank you.**

\*\*\*\*\*  
\*\*\* TX REPORT \*\*\*  
\*\*\*\*\*

TRANSMISSION OK

TX/RX NO	2831
DESTINATION TEL #	15712730459
DESTINATION ID	
ST. TIME	03/22 10:21
TIME USE	01'28
PAGES SENT	11
RESULT	OK

**FAX TRANSMITTAL SHEET  
KLAUBER & JACKSON  
ATTORNEYS AT LAW  
CONTINENTAL PLAZA  
411 HACKENSACK AVENUE  
HACKENSACK, NJ 07601**

**PHONE (201) 487-5800**

**FAX (201) 343-1684 OR  
(201) 343-7544**

**TO : USPTO - PCT Legal Administrator**  
**FROM : David A. Jackson, Esq.**  
**RE : Serial No.: 10/524,910 - Attorney Docket No. 2543-1-040PCT/US  
REQUEST FOR CORRECTED FILING RECEIPT - TITLE**  
**DATE : March 22, 2006**  
**FAX NO. : (571) 273-0459**

**TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 11**

**MESSAGE:**

Attached herewith is a Request for Corrected Filing Receipt (correction to the Title of the application). Since this is a National Phase Filing, we have been advised that such requests should be directed to the PCT Legal Administrator.

Kindly process the correction to the Title to read: *PTK7 Protein Involvement in Carcinoma* and issue a Corrected Filing Receipt.

\*\*\*\*\*  
\*\*\* RX REPORT \*\*\*  
\*\*\*\*\*

RECEPTION OK

TX/RX NO	6223
RECIPIENT ADDRESS	
DESTINATION ID	
ST. TIME	07/26 09:57
TIME USE	01'53
PGS.	14
RESULT	OK

**FAX TRANSMITTAL SHEET**  
**KLAUBER & JACKSON**  
**ATTORNEYS AT LAW**  
**CONTINENTAL PLAZA**  
**411 HACKENSACK AVENUE**  
**HACKENSACK, NJ 07601**

**PHONE (201) 487-5800**

*2ND REQUEST*  
*4/28/06*

**FAX (201) 343-1684 OR**  
**(201) 343-7544**

**RECEIVED**  
28 APR 2006  
Legal Staff  
International Division

**TO : USPTO - PCT Legal Administrator**  
**FROM : David A. Jackson, Esq.**  
**RE : Serial No.: 10/524,910 - Attorney Docket No. 2543-1-040PCT/US**  
**REQUEST FOR CORRECTED FILING RECEIPT - TITLE**  
**DATE : March 22, 2006**  
**FAX NO. : (571) 273-0459**

**TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET):** 12

**MESSAGE:**

Attached herewith is a Request for Corrected Filing Receipt (correction to the Title of the application). Since this is a National Phase Filing, we have been advised that such requests should be directed to the PCT Legal Administrator.

Kindly process the correction to the Title to read: *PTK7 Protein Involvement in Carcinoma* and issue a Corrected Filing Receipt.

**Thank you.**

**NOTE:** The information contained in this facsimile message is attorney-client privileged and contains confidential information intended only for the use of the individual named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copy of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone (201-487-5800) and return the original transmission to us by mail without making a copy.



PATENT  
2543-1-040PCT/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) : Jonathan Alexander Terrett  
SERIAL NO. : 10/524,910  
FILED : January 12, 2006  
FOR : PTK7 PROTEIN INVOLVEMENT IN CARCINOMA

CERTIFICATE OF FACSIMILE UNDER 37 CFR 1.8

I hereby certify that this correspondence is being transmitted via facsimile to  
addressed to PCT Legal Administrator, Commissioner For Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450 on MARCH 22, 2006.

Karen Garipoli  
(Name of Transmitter)

Karen Garipoli 3/22/06  
(Signature and Date)

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Attention: PCT Legal Administrator

Dear Sir:

Applicants hereby request that a corrected Formal Filing Receipt (PTO-103X) be issued to  
correct the title in the above-identified Application.

Please correct the title from "Protein Involved in Carcinoma" to

**--PTK7 PROTEIN INVOLVEMENT IN CARCINOMA--**


as it appears on the first page of the Application as filed on February 17, 2005, as well as on the  
executed Declaration filed with the Response to the Notification of Missing Requirements on  
January 12, 2006. Copies of the first page of the application and the executed Declaration are  
attached herewith.

PATENT  
2543-1-040PCT/US

A copy of the filing receipt with the requested correction marked in red is also enclosed.

Applicants accordingly request that the records of the U.S. Patent and Trademark Office  
be corrected to reflect the correct title.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "David A. Jackson", written over a horizontal line.

David A. Jackson  
Attorney for Applicant  
Registration No. 26,742

KLAUBER & JACKSON LLC  
411 Hackensack Avenue, 4<sup>th</sup> Floor  
Hackensack, NJ 07601  
(201) 487-5800

Enclosures



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/524,910	01/12/2006	1615	1980	2543-1-040PCT/US	10	31	5

23565  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NJ 07601

RECEIVED

MAR 20 2006

KLAUBER &amp; JACKSON

CONFIRMATION NO. 1458

FILING RECEIPT

OC000000018267677

Date Mailed: 03/15/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Jonathan Alexander Terrett, Berkshire, GBN, UNITED KINGDOM;

Power of Attorney: The patent practitioners associated with Customer Number 23565.

## Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB03/03421 08/06/2003

## Foreign Applications

UNITED KINGDOM 0219776.2 08/24/2002

Projected Publication Date: 06/22/2006

Non-Publication Request: No

Early Publication Request: No

Title: *PTK7* *involvement* Protein involved in carcinoma

Preliminary Class

*Correct title to read:*

*PTK7 Protein Involvement  
IN CARCINOMA*

*3/22/06*

424

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce Initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

### LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the

national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau.(43) International Publication Date  
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number  
**WO 2004/017992 A3**(51) International Patent Classification: A61K 39/395,  
38/17, A61P 35/00(74) Agent: **BLAKEY, Allison, Jane**; Oxford GlycoSciences  
(UK) Ltd, The Forum, 86 Milton Park, Abingdon, Oxford-  
shire OX14 4RY (GB).(21) International Application Number:  
PCT/GB2003/003421

(22) International Filing Date: 6 August 2003 (06.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0219776.2 24 August 2002 (24.08.2002) GB

(71) Applicant (for all designated States except US): **OXFORD  
GLYCOSCIENCES (UK) LTD [GB/GB]**; Attn: Mary  
Gadsden, The Forum, 86 Milton Park, Abingdon, Oxford-  
shire OX14 4RY (GB).


(72) Inventor: and

(75) Inventor/Applicant (for US only): **TERRETT,  
Jonathan, Alexander [GB/GB]**; The Forum, Milton  
Park, Abingdon, Oxfordshire OX14 4RY (GB).(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(Continued on next page)

(54) Title: **PTK7 PROTEIN INVOLVEMENT IN CARCINOMA**

(57) Abstract: The present invention provides a polypeptide, PTK7, of use in the treatment and/or prophylaxis of carcinoma. Also provided are agents which interact with or modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of PTK7 in the diagnosis of carcinoma.

WO 2004/017992 A3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371</b>		<b>ATTORNEY'S DOCKET NUMBER</b> 2543-1-040PCT/US
<b>INTERNATIONAL APPLICATION NO.</b> PCT/GB2003/003421	<b>INTERNATIONAL FILING DATE</b> August 6, 2003	<b>PRIORITY DATE CLAIMED</b> August 24, 2002
<b>TITLE OF INVENTION</b> PTK7 PROTEIN INVOLVEMENT IN CARCINOMA		
<b>APPLICANT(S) FOR DO/EO/US</b> JONATHAN ALEXANDER TERRETT		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li><input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li><input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li><input checked="" type="checkbox"/> The US has been elected (Article 31).</li> <li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li><input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li><input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li><input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li><input type="checkbox"/> is attached hereto.</li> <li><input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li><input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li><input type="checkbox"/> have been communicated by the International Bureau.</li> <li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li><input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li><input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li><input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <b>UNEXECUTED</b></li> <li><input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
Items 11 to 20 below concern document(s) or information included:		
<ol style="list-style-type: none"> <li><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li><input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li><input checked="" type="checkbox"/> A preliminary amendment.</li> <li><input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li> <li><input type="checkbox"/> A substitute specification.</li> <li><input type="checkbox"/> A power of attorney and/or change of address letter.</li> <li><input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.</li> <li><input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li><input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li><input checked="" type="checkbox"/> Other items or information: <b>DRAWINGS-10 SHEETS-FIG.1-9; COPY ISR; COPY IPR; SEQ LIST-PAPER; SEQ. STATEMENT; COPY PCT REQ; COPY NOTICE CONCERN TRANSMIT PRIORITY; COPY DEMAND</b></li> </ol>		

This collection of information is required by 37 CFR 1.414 and 1.481-1.482. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No.:2543-1-040PCT/US

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**PTK7 PROTEIN INVOLVEMENT IN CARCINOMA**

the Specification of which

☒ is attached hereto

☒ was filed on August 6, 2003

as International Application No. PCT/GB2003/003421

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

<u>APPLICATION</u>	<u>PRIOR FOREIGN FILED APPLICATION(S)</u>		<u>PRIORITY</u>
<u>NUMBER</u>	<u>COUNTRY</u>	<u>(MONTH/DAY/YYYY)</u>	<u>CLAIMED</u>
0219776.2	Great Britain	August 24, 2002	YES



Attorney Docket No.:2543-1-040PCT/US

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER(S)FILING DATE (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent  
Application No.

PCT Parent  
Number

Parent Filing  
(MM/DD/YYYY)

Parent Patent  
Number (if applicable)

I hereby appoint as my attorneys or agents the registered persons identified under

**Customer No. 23565**

for the law firm of Klauber & Jackson, said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to **Customer No. 23565**.

DAVID A. JACKSON, ESQ.  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

Attorney Docket No.:2543-1-040PCT/US

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST OR SOLE INVENTOR: Jonathan Alexander TERRETT

COUNTRY OF CITIZENSHIP: Great Britain

FULL RESIDENCE ADDRESS: 208 Bath Road  
Slough, Berkshire  
SL1, 3WE  
Great Britain

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR  \_\_\_\_\_DATE Feb 17<sup>th</sup> 2005

\*\*\*\*\*  
\*\*\* TX REPORT \*\*\*  
\*\*\*\*\*

TRANSMISSION OK

TX/RX NO	2831
DESTINATION TEL #	15712730459
DESTINATION ID	
ST. TIME	03/22 10:21
TIME USE	01'28
PAGES SENT	11
RESULT	OK

**FAX TRANSMITTAL SHEET  
KLAUBER & JACKSON  
ATTORNEYS AT LAW  
CONTINENTAL PLAZA  
411 HACKENSACK AVENUE  
HACKENSACK, NJ 07601**

**PHONE (201) 487-5800**

**FAX (201) 343-1684 OR  
(201) 343-7544**

**TO : USPTO - PCT Legal Administrator**  
**FROM : David A. Jackson, Esq.**  
**RE : Serial No.: 10/524,910 - Attorney Docket No. 2543-1-040PCT/US  
REQUEST FOR CORRECTED FILING RECEIPT - TITLE**  
**DATE : March 22, 2006**  
**FAX NO. : (571) 273-0459**

**TOTAL NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 11**

**MESSAGE:**

Attached herewith is a Request for Corrected Filing Receipt (correction to the Title of the application). Since this is a National Phase Filing, we have been advised that such requests should be directed to the PCT Legal Administrator.

Kindly process the correction to the Title to read: *PTK7 Protein Involvement in Carcinoma* and issue a Corrected Filing Receipt.

\*\*\*\*\*  
\*\*\* RX REPORT \*\*\*  
\*\*\*\*\*

RECEPTION OK

TX/RX NO	5652
RECIPIENT ADDRESS	
DESTINATION ID	
ST. TIME	04/28 15:53
TIME USE	01'33
PGS.	12
RESULT	OK